Vertex Pharma Reports Positive Phase 2 Data With VX-150 Proof-of-Concept Study

生物医药公司Vertex第 II 期 VX -150概念验证研究数据显示阳性

2018-12-19 10:49:22 RTTNews

本文共283个字,阅读需1分钟

Vertex Pharmaceuticals Inc. (VRTX) reported positive results of a Phase 2 study of the investigational NaV1.8 inhibitor VX-150 in patients with pain caused by small fiber neuropathy. The company said the study met its primary endpoint and showed that treatment with VX-150 demonstrated statistically significant and clinically meaningful pain reduction at Week 6. VX-150 was generally well tolerated in this study. Jeffrey Leiden, CEO of Vertex, said: "These results show a potential path for the treatment of pain at a time when there is great clinical and societal need for new medicines. We continue to progress VX-150 toward pivotal development and also plan to advance additional NaV1.8 pain medicines into clinical development beginning in 2019."
Vertex Pharmaceuticals Inc .( VRTX )公司 NAV1.8抑制剂 VX-150在小纤维神经病变引起的疼痛患者中的II期研究结果显示阳性。该公司表示,研究满足了其主要终点,研究表明, VX-150治疗在第6周出现统计意义和临床意义上的疼痛减轻。在这项研究中, VX-150总体上耐受性良好。 Vertex 首席执行官杰Jeffrey Leiden表示:“在临床和社会对新药需求巨大之际,这些结果显示出治疗疼痛的潜在途径。我们继续推进 VX-150向关键发展方向迈进,并计划从2019年开始将额外的 NaV1.8止痛药推进到临床开发中。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文